What is William Blair’s Estimate for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Analysts at William Blair issued their Q1 2025 earnings estimates for shares of FibroGen in a research report issued on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the biopharmaceutical company will post earnings per share of $0.02 for the quarter. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.72) EPS.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $24.91 million.

Several other equities analysts also recently weighed in on FGEN. StockNews.com began coverage on shares of FibroGen in a research note on Friday, March 14th. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research note on Tuesday.

FibroGen Stock Down 5.9 %

Shares of FGEN opened at $0.34 on Thursday. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.80. The stock has a market cap of $33.91 million, a PE ratio of -0.27 and a beta of 0.82. The firm’s fifty day moving average is $0.49 and its two-hundred day moving average is $0.43.

Institutional Trading of FibroGen

Several large investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC acquired a new position in shares of FibroGen during the 4th quarter valued at about $27,000. Velan Capital Investment Management LP purchased a new stake in shares of FibroGen in the 4th quarter valued at approximately $42,000. XTX Topco Ltd grew its stake in shares of FibroGen by 423.8% in the 4th quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC raised its position in shares of FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the period. Finally, FMR LLC lifted its holdings in FibroGen by 21.8% in the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the last quarter. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.